Patterns of Response in Patients With Pretreated Metastatic Melanoma Who Received Ipilimumab 3 Mg/Kg in a European Expanded Access Program: Five Illustrative Case Reports
Cancer Investigation - United States
doi 10.3109/07357907.2012.727934
Full Text
Open PDFAbstract
Available in full text
Date
October 8, 2012
Authors
Publisher
Informa UK Limited